The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.
 
Toshihiko Doi
No Relationships to Disclose
 
Yoon-Koo Kang
No Relationships to Disclose
 
Kei Muro
No Relationships to Disclose
 
Yizhou Jiang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Rajul K. Jain
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Richard Lizambri
Employment - Amgen
Stock and Other Ownership Interests - Amgen